GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2008

Wyeth Takes Over Thiakis for $30M

  • Wyeth Pharmaceuticals acquired Thiakis for approximately $30 million. Additional payments of up to $120 million will be payable upon the achievement of certain development milestones.

    Thiakis' lead product candidate, TKS1225, is being studied for the treatment of obesity and other co-morbidities. TKS1225 and related compounds are synthetic versions of the natural gastrointestinal peptide oxyntomodulin.

    “Thiakis' research and development program fits well with our goal of addressing the medical burden of obesity in a targeted manner using biologic-based therapies," says Mikael Dolsten, M.D., Ph.D., president, Wyeth Research.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?